The DOI matches its Crossref record.
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Abstract
We studied the accumulation of neurofibrillary tangles (NFTs) and senile plaques (SPs) in 10 Alzheimer's disease patients who had been examined during life. We counted NFTs and SPs in 13 cytoarchitectural regions representing limbic, primary sensory, and association cortices, and in subcortical neurotransmitter-specific areas. The degree of neuropathologic change was compared with the severity of dementia, as assessed by the Blessed Dementia Scale and duration of illness. We found that (1) the severity of dementia was positively related to the number of NFTs in neocortex, but not to the degree of SP deposition; (2) NFTs accumulate in a consistent pattern reflecting hierarchic vulnerability of individual cytoarchitectural fields; (3) NFTs appeared in the entorhinal cortex, CA1/subiculum field of the hippocampal formation, and the amygdala early in the disease process; and (4) the degree of SP deposition was also related to a hierarchic vulnerability of certain brain areas to accumulate SPs, but the pattern of SP distribution was different from that of NFT.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have shown that their number and location correlates with neuronal loss, disease severity and clinical course [65, 66].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [66]
In the citing paper
“Neurofibrillary tangles and quantitative neuronal loss, but not amyloid plaques, have been found to correlate with disease severity and dementia duration [21–23].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [22]
In the citing paper
“to correlate with measures of cognitive decline (Arriagada et al., 1992) in humans.”
From Network analysis identifies strain-dependent response to tau and tau seeding-associated genes (2023) · cites this paper as Arriagada et al., 1992
In the citing paper
“In AD patients, the clinical severity of dementia strongly correlates with the load of pathological tau aggregates. 3 , 4”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [3]
In the citing paper
“Correlations between NFT density and clinical symptoms, such as a cognitive decline in AD, have been demonstrated [11, 12].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [11]
In the citing paper
“Increasing evidence demonstrates that the cognitive dysfunction and severity of the disease are more related to tau pathology [11–14].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [11]
In the citing paper
“Tau has received increasing attention as a potential therapeutic target, since evidence indicates that tau pathology is more associated with cognitive dysfunction.”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [11]
In the citing paper
“NFTs and quantitative neuronal loss may be more closely correlated with disease severity and dementia progression than the amyloid plaque burden [20–22].”
From Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update (2023) · cites this paper as [21]
In the citing paper
“the best pathological correlate for clinical symptoms to date is the extent of NFT formation (Arriagada et al., 1992; Brier et al., 2016; Giannakopoulos et al., 2003)”
From Selective Neuronal Vulnerability in Alzheimer’s Disease: A Network-Based Analysis (2020) · cites this paper as Arriagada et al., 1992
In the citing paper
“a large number of studies have arrived at a common finding, namely, there is a strong link between neocortical NFTs and cognitive decline (Tomlinson et al., 1970; Duyckaerts et al., 1990, 1997, 1998; Mckee et al., 1991; Arriagada et al., 1992;”
From Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models (2014) · cites this paper as Arriagada et al., 1992
Citations
Cites
Still being checked.
Cited by
Sorted by citations
Items 801–900 of 1,025
Adav, S. S., & Sze, S. K. (2016) · Molecular Brain · doi:10.1186/s13041-016-0272-9 · Cited by 75
Yang, S., Chiu, M., Chen, T., & Horng, H. E. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0075-7 · Cited by 74
Sales, T. A., Prandi, I. G., de Castro, A. A., Leal, D. H. S., da Cunha, E. F. F., Kuča, K., & Ramalho, T. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081829 · Cited by 73
New Neuropathological Criteria for Alzheimer Disease
Hyman, B. T. (1998) · Archives of Neurology · doi:10.1001/archneur.55.9.1174 · Cited by 73
Self-citationColurso, G. J., Nilson, J. E., & Vervoort, L. G. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00512-5 · Cited by 73
Chapter 26 Reduced neuronal activity and reactivation in Alzheimer's disease
Swaab, D. F., Lucassen, P. J., Salehi, A., Scherder, E., Someren, E. J. W. V., & Verwer, R. W. H. (1998) · Progress in brain research · doi:10.1016/s0079-6123(08)64027-3 · Cited by 74
Grundman, M., Jack, C. R., Petersen, R. C., Kim, H. T., Taylor, C., Datvian, M., Weiner, M., DeCarli, C. S., DeKosky, S. T., van Dyck, C. H., et al. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:20:3:241 · Cited by 77
Ultrastructural and biochemical classification of pathogenic tau, α-synuclein and TDP-43
Tarutani, A., Adachi, T., Akatsu, H., Hashizume, Y., Hasegawa, K., Saito, Y., Robinson, A., Mann, D. M. A., Yoshida, M., Murayama, S., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02426-3 · Cited by 74
Misregulation of Tau Alternative Splicing in Neurodegeneration and Dementia
Andreadis, A. (2006) · Progress in molecular and subcellular biology · doi:10.1007/978-3-540-34449-0_5 · Cited by 72
Alzheimer's Disease and Anesthesia
Papon, M.-A., Whittington, R. A., Khoury, N. B. E., & Planel, E. (2011) · Frontiers in Neuroscience · doi:10.3389/fnins.2010.00272 · Cited by 70
Caspases as therapeutic targets
Howley, B. A., & Fearnhead, H. O. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00292.x · Cited by 73
Mechanisms of AD neurodegeneration may be independent of Aβ and its derivatives
Robakis, N. K. R. K. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.022 · Cited by 72
Rentz, D. M., Mormino, E. C., Papp, K. V., Betensky, R. A., Sperling, R. A., & Johnson, K. A. (2016) · Brain Imaging and Behavior · doi:10.1007/s11682-016-9640-4 · Cited by 74
Acetylated tau in Alzheimer's disease: An instigator of synaptic dysfunction underlying memory loss
Tracy, T. E., & Gan, L. (2017) · BioEssays · doi:10.1002/bies.201600224 · Cited by 72
Higuchi, M., Iwata, N., & Saido, T. C. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.02.013 · Cited by 73
Preclinical AD Workgroup staging: Pathological correlates and potential challenges
Jicha, G. A., Abner, E. L., Schmitt, F. A., Kryscio, R. J., Riley, K. P., Cooper, G. E., Stiles, N., Mendiondo, M. S., Smith, C. D., Van Eldik, L. J., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.018 · Cited by 71
Kalaitzakis, M. E., Walls, A. J., Pearce, R. K. B., & Gentleman, S. M. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.10.005 · Cited by 72
Keating, D. J., Chen, C., & Pritchard, M. A. (2006) · Ageing Research Reviews · doi:10.1016/j.arr.2005.11.001 · Cited by 76
Preserved frontal memorial processing for pictures in patients with mild cognitive impairment
Ally, B. A., McKeever, J. D., Waring, J. D., & Budson, A. E. (2009) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2009.03.015 · Cited by 73
Mak, E., Gabel, S., Mirette, H., Su, L., Williams, G. B., Waldman, A., Wells, K., Ritchie, K., Ritchie, C., & O’Brien, J. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.10.001 · Cited by 71
Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer’s Disease
Tuwaig, M., Savard, M., Jutras, B., Poirier, J., Collins, D. L., Rosa‐Neto, P., Fontaine, D. J., & Breitner, J. C. S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170545 · Cited by 72
Pathological Determinants of the Transition to Clinical Dementia in Alzheimer's Disease
Royall, D. R., Palmer, R. F., Mulroy, A. R., Polk, M. J., Román, G. C., David, J. P., & Delacourte, A. (2002) · Experimental Aging Research · doi:10.1080/03610730252800166 · Cited by 71
Kubo, T., Kumagae, Y., Miller, C. A., & Kaneko, I. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.3.248 · Cited by 71
Liu, W., Zhao, L., Blackman, B. A., Parmar, M. S., Wong, M. Y., Woo, T., Yu, F., Chiuchiolo, M. J., Sondhi, D., Kaminsky, S. M., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.2016-16.2016 · Cited by 73
Furcila, D., DeFelipe, J., & Alonso‐Nanclares, L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180173 · Cited by 73
The Role of Cholesterol Metabolism in Alzheimer’s Disease
Sun, J.-H., Yu, J.-T., & Tan, L. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8749-y · Cited by 70
Jiang, X., Jia, L., Li, X., Cheng, X., Xie, J., Ma, Z., Xu, W., Liu, Y., Yao, Y., Du, L., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121837 · Cited by 69
Neuropathology of Alzheimer's Disease
Mott, R. T., & Hulette, C. M. (2005) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2005.09.003 · Cited by 71
Kim, D., Su, J. H., & Cotman, C. W. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01724-2 · Cited by 72
The cytoskeleton in Alzheimer disease
Terry, R. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6467-9_12 · Cited by 70
Oligomer Diversity during the Aggregation of the Repeat Region of Tau
Kjærgaard, M., Dear, A. J., Kundel, F., Qamar, S., Meisl, G., Knowles, T. P. J., & Klenerman, D. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00250 · Cited by 67
Islam, T., Hill, E., Abrahamson, E. E., Servaes, S., Smirnov, D. S., Zeng, X., Sehrawat, A., Chen, Y., Kac, P. R., Kvartsberg, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03400-0 · Cited by 76
Ma, D., Chen, F., Xu, W., Yue, W., Yuan, G., & Yang, Y. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13248 · Cited by 75
An update on drug treatment options of Alzheimer's disease
Allgaier, M. (2014) · Frontiers in bioscience · doi:10.2741/4285 · Cited by 69
García‐Sierra, F., Hauw, J. J., Duyckaerts, C. J., Wischik, C. M., Luna‐Muñoz, J., & Mena, R. (2000) · Acta Neuropathologica · doi:10.1007/s004010051189 · Cited by 69
Neurodegeneration and plasticity
Arendt, T. (2004) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2004.07.007 · Cited by 69
Gertz, H., Xuereb, J. H., Huppert, F. A., Brayne, C., McGee, M. A., Paykel, E. S., Harrington, C. R., Mukaetova-Ladinska, E., Arendt, T., & Wischik, C. M. (1998) · Acta Neuropathologica · doi:10.1007/s004010050780 · Cited by 69
Ulloa, L., de Garcini, E. M., Gómez‐Ramos, P., Morán, M. A., & Ávila, J. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90081-7 · Cited by 69
McKeel, D. W., Price, J. L., Miller, J. P., Grant, E. A., Xiong, C., Berg, L., & Morris, J. C. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.10.1028 · Cited by 68
Translational approaches to understanding resilience to Alzheimer’s disease
Neuner, S. M., Telpoukhovskaia, M., Menon, V., O’Connell, K. M. S., Hohman, T. J., & Kaczorowski, C. C. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.02.005 · Cited by 68
Quantifying the Pathophysiological Timeline of Alzheimer's Disease
Yang, E., Farnum, M. A., Lobanov, V. S., Schultz, T., Raghavan, N., Samtani, M. N., Novak, G., Narayan, V. A., DiBernardo, A., & Initiative1, A. T. A. D. N. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110551 · Cited by 66
Is Tau Aggregation Toxic or Protective?
Congdon, E. E., & Duff, K. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14415 · Cited by 70
Curcumin-induced upregulation of the anti-tau cochaperone BAG2 in primary rat cortical neurons
Patil, S. P., Tran, N. T., Geekiyanage, H., Liu, L., & Chan, C. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.09.008 · Cited by 70
Ser9 phosphorylation causes cytoplasmic detention of I2PP2A/SET in Alzheimer disease
Yu, G., Yan, T., Feng, Y., Liu, X., Xia, Y., Luo, H., Wang, J., & Wang, X. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.025 · Cited by 68
Arif, M., Wei, J., Zhang, Q., Liu, F., Basurto‐Islas, G., Grundke, I., & Iqbal, K. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.565358 · Cited by 68
FoxO mediates APP-induced AICD-dependent cell death
Wang, X., Wang, Z., Chen, Y., Huang, X., Hu, Y., Zhang, R., Ho, M. S.-C., & Xue, L. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.196 · Cited by 70
A amyloid deposition in the language system and how the brain responds
Nelissen, N., Vandenbulcke, M., Fannes, K., Verbruggen, A., Peeters, R. R., Dupont, P. J., Laere, K. V., Bormans, G. M., & Vandenberghe, R. R. (2007) · Brain · doi:10.1093/brain/awm133 · Cited by 70
The Molecular Pathology of Alzheimer's Disease
Harrington, C. R. (2012) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2011.11.003 · Cited by 70
Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease
Phillips, J. S., Das, S. R., McMillan, C. T., Irwin, D. J., Roll, E. E., Da Re, F., Nasrallah, I. M., Wolk, D. A., & Grossman, M. (2018) · Human Brain Mapping · doi:10.1002/hbm.23874 · Cited by 68
Peptides as Potential Therapeutics for Alzheimer’s Disease
Ribarič, S. (2018) · Molecules · doi:10.3390/molecules23020283 · Cited by 69
Clinical Validity of Aß-Protein Deposition Staging in Brain Aging and Alzheimer Disease
Gold, G., Kövari, E., Corte, G., Herrmann, F. R., Canuto, A., Bussière, T., Hof, P. R., Bouras, C., & Giannakopoulos, P. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.10.946 · Cited by 67
Molecular misreading: a new type of transcript mutation expressed during aging
van Leeuwen, F. W. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00151-2 · Cited by 68
Buck, B. H. (1997) · Brain · doi:10.1093/brain/120.7.1229 · Cited by 73
Amoureux, M., Gool, D. V., Herrero, M. T., Dom, R., Colpaert, F. C., & Pauwels, P. J. (1997) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815170 · Cited by 68
Role of glycosaminoglycans in determining the helicity of paired helical filaments.
Arrasate, M., Pérez, M., Valpuesta, J., & Ávila, J. (1997) · Europe PMC (PubMed Central) · Cited by 68
Ikeda, M., Tanabe, H., Nakagawa, Y., Kazui, H., Oi, H., Yamazaki, H., Harada, K., & Nishimura, T. (1994) · Neuroradiology · doi:10.1007/bf00599184 · Cited by 68
Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer's disease
Bennett, D. A., Cochran, E. J., Saper, C. B., Leverenz, J. B., Gilley, D. W., & Wilson, R. S. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90043-b · Cited by 67
Dissecting the complexities of Alzheimer disease with in vitro models of the human brain
Blanchard, J., Victor, M. B., & Tsai, L. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00578-6 · Cited by 68
Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity
Moscoso, A., Heeman, F., Raghavan, S., Costoya‐Sánchez, A., van Essen, M., Mainta, I., Camacho, V., Fonseca, O. D. R., Silva‐Rodríguez, J., Perissinotti, A., et al. (2025) · JAMA · doi:10.1001/jama.2025.7817 · Cited by 74
Perreault, S., Bousquet, O., Lauzon, M., Paiement, J., & Leclerc, N. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181a1fc49 · Cited by 67
Pickett, E. K., Henstridge, C. M., Allison, E. K., Pitstick, R., Pooler, A. M., Wegmann, S., Carlson, G. A., Hyman, B. T., & Spires‐Jones, T. L. (2017) · Synapse · doi:10.1002/syn.21965 · Cited by 68
Self-citationBendiske, J., Caba, E., Brown, Q. B., & Bahr, B. A. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.7.640 · Cited by 67
GlutamateNMDA receptor NR1 subunit mRNA expression in Alzheimer's disease
Hynd, M. R., Scott, H. L., & Dodd, P. R. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00409.x · Cited by 66
Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions
Villemagne, V. L., & Okamura, N. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.09.002 · Cited by 70
Viswanathan, G. K., Shwartz, D., Losev, Y., Arad, E., Shemesh, C., Pichinuk, E., Engel, H., Raveh, A., Jelinek, R., Cooper, I., et al. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03312-0 · Cited by 67
Imbimbo, B. P., Ippati, S., Watling, M., & Imbimbo, C. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106631 · Cited by 69
Ricciarelli, R., d'Abramo, C., Zingg, J.-M., Giliberto, L., Markesbery, W., Azzi, A., Marinari, U. M., Pronzato, M. A., & Tabaton, M. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.01.007 · Cited by 66
Gratuze, M., Julien, J., Petry, F. R., Morin, F., & Planel, E. (2017) · Scientific Reports · doi:10.1038/srep46359 · Cited by 68
Neuroepigenetic mechanisms in disease
Christopher, M. A., Kyle, S. M., & Katz, D. J. (2017) · Epigenetics & Chromatin · doi:10.1186/s13072-017-0150-4 · Cited by 69
Preuß, U., & Mandelkow, E. (1998) · European Journal of Cell Biology · doi:10.1016/s0171-9335(98)80032-0 · Cited by 66
Alzheimer's disease-related synapse loss in the cingulate cortex
Scheff, S. W., & PRICE, D. A. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3509 · Cited by 68
Visualization of regional tau deposits using 3H-THK5117 in Alzheimer brain tissue
Lemoine, L., Saint‐Aubert, L., Marutle, A., Antoni, G., Eriksson, J., Ghetti, B. F., Okamura, N., Nennesmo, I., Gillberg, P.-G., & Nordberg, A. K. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0220-4 · Cited by 65
Amygdalar atrophy in symptomatic Alzheimer's disease based on diffeomorphometry: the BIOCARD cohort
Miller, M. I., Laurent Younes, B., Ratnanather, J. T., Brown, T., Trinh, H., Lee, D. S., Tward, D. J., Mahon, P. B., Mori, S., & Albert, M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.032 · Cited by 64
Advances in the development of tau PET radiotracers and their clinical applications
Okamura, N., Harada, R., Furukawa, K., Furumoto, S., Tago, T., Yanai, K., Arai, H., & Kudo, Y. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2015.12.010 · Cited by 68
Koppensteiner, P., Trinchese, F., Fà, M., Puzzo, D., Gulisano, W., Yan, S., Poussin, A., Liu, S., Orozco, I. J., Dale, E., et al. (2016) · Scientific Reports · doi:10.1038/srep32553 · Cited by 67
Delizannis, A. T., Nonneman, A., Tsering, W., Bondt, A. D., den Wyngaert, I. V., Zhang, B., Meymand, E. S., Olufemi, M. F., Koivula, P. P., Maimaiti, S., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01251-1 · Cited by 71
Gene expression parallels synaptic excitability and plasticity changes in Alzheimer’s disease
Saura, C. A., Parra‐Damas, A., & Enríquez-Barreto, L. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00318 · Cited by 65
Hayes, A., Thaker, U., Iwatsubo, T., Pickering-Brown, S. M., & Mann, D. M. A. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00888-1 · Cited by 65
Dong, H., Yuede, C. M., Coughlan, C. A., Lewis, B. L., & Csernansky, J. G. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.53 · Cited by 65
Leoni, V., Solomon, A., & Kivipelto, M. (2010) · Biochemical Society Transactions · doi:10.1042/bst0381021 · Cited by 68
Dynamics of Plaque Formation in Alzheimer's Disease
Urbanc, B., Cruz, L., Buldyrev, S. V., Havlin, S., Irizarry, M. C., Stanley, E., & Hyman, B. T. (1999) · Biophysical Journal · doi:10.1016/s0006-3495(99)77295-4 · Cited by 65
Self-citationKovalevich, J., Cornec, A., Yao, Y., James, M., Crowe, A., Lee, V. M. Y., Trojanowski, J. Q., Smith, A. B., Ballatore, C., & Brunden, K. R. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.231175 · Cited by 66
Dam, D. V., Vermeiren, Y., Dekker, A. D., Naudé, P. J. W., & Deyn, P. P. D. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160502123607 · Cited by 68
β-Amyloid Induces Pathology-Related Patterns of Tau Hyperphosphorylation at Synaptic Terminals
Wu, H., Kuo, P.-C., Wang, Y.-T., Lin, H.-T., Roe, A. D., Wang, B. Y., Han, C., Hyman, B. T., Chen, Y., & Tai, H. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly059 · Cited by 72
Self-citationIn vivoimaging reveals reduced activity of neuronal circuits in a mouse tauopathy model
Marinković, P., Blumenstock, S., Goltstein, P. M., Korzhova, V., Peters, F., Knebl, A., & Herms, J. W. (2019) · Brain · doi:10.1093/brain/awz035 · Cited by 63
Immunocytochemical characterization of glial fibrillary tangles in Alzheimer's disease brain.
Nishimura, M., Tomimoto, H., Suenaga, T., Namba, Y., Ikeda, K., Akiguchi, I., & Kimura, J. (1995) · Europe PMC (PubMed Central) · Cited by 65
Kurylo, D. D., Corkin, S., F., I. R. J., & Growdon, J. H. (1996) · Neuropsychology · doi:10.1037/0894-4105.10.1.74 · Cited by 65
Self-citationVogt, B. A., Vogt, L. J., Vrana, K. E., Gioia, L., Meadows, R. S., Challa, V. R., Hof, P. R., & Van Hoesen, G. W. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6852 · Cited by 64
Transgenic Mouse Models of Alzheimer’s Disease: Behavioral Testing and Considerations
Bryan, K. J., Lee, H., Perry, G. L., Smith, M. A., & Casadesús, G. (2009) · Europe PMC (PubMed Central) · Cited by 64
Anti-dementia Activity of Nobiletin, a Citrus Flavonoid: A Review of Animal Studies
Nakajima, A., Ohizumi, Y., & Yamada, K. (2014) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2014.12.2.75 · Cited by 65
Dopamine D2 Receptor Antagonism Suppresses Tau Aggregation and Neurotoxicity
McCormick, A. V., Wheeler, J. M., Guthrie, C. R., Liachko, N. F., & Kraemer, B. C. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.08.027 · Cited by 64
Role of Tau Protein in Neuronal Damage in Alzheimer's Disease and Down Syndrome
Cárdenas, A. M., Ardiles, Á. O., Barraza, N., Báez‐Matus, X., & Caviedes, P. A. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.10.012 · Cited by 68
18F-florbetaben Aβ imaging in mild cognitive impairment
Ong, K. T., Villemagne, V. L., Bahar‐Fuchs, A., Lamb, F., Chételat, G., Raniga, P., Mulligan, R. S., Salvado, O., Pütz, B., Roth, K. S., et al. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt158 · Cited by 68
Woodling, N. S., & Andreasson, K. I. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00016 · Cited by 62
Extracellular tau induces microglial phagocytosis of living neurons in cell cultures
Pampuščenko, K., Morkūnienė, R., Šneideris, T., Smirnovas, V., Budvytytė, R., Valinčius, G., Brown, G. C., & Borutaitė, V. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14940 · Cited by 64
FRET-based Tau seeding assay does not represent prion-like templated assembly of Tau filaments
Kaniyappan, S., Tepper, K., Biernat, J., Chandupatla, R., Hübschmann, S., Irsen, S. H., Bicher, S., Klatt, C., Mandelkow, E., & Mandelkow�, E. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00389-1 · Cited by 65
Perspectives on the Amyloid-β Cascade Hypothesis
Lee, H., Casadesús, G., Zhu, X., Joseph, J. A., Perry, G. L., & Smith, M. A. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6205 · Cited by 66
Sensitivity to ageing of the limbic dopaminergic system: a review
Barili, P., Carolis, G. D., Zaccheo, D., & Amenta, F. (1998) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(98)00104-3 · Cited by 68
Dobarro, M., Orejana, L., Aguirre, N., & Ramírez, M. J. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.047 · Cited by 63
Protein Tau: Prime Cause of Synaptic and Neuronal Degeneration in Alzheimer's Disease
Crespo‐Biel, N., Theunis, C., & LEUVEN, F. V. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/251426 · Cited by 69
Metadata
- Authors
- Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T.
- Affiliations
- Harvard University (US)
- ORCID
- Hyman, Bradley T.
- Venue
- Neurology
- Published
- 1992-03
- Volume
- 42
- Issue
- 3
- Pages
- 631-631
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2053116497
- Cited by
- 2,668
- References
- 0
- Citations by year
- 2026: 54 · 2025: 89 · 2024: 81 · 2023: 101 · 2022: 89 · 2021: 141 · 2020: 135 · 2019: 131 · 2018: 96 · 2017: 112 · 2016: 132 · 2015: 101 · 2014: 106 · 2013: 93 · 2012: 97
- FWCI
- 28.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG-08487, P50 AG05134, P50AG005134)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, neurofibrillary tangles, amyloid plaques, dementia severity, disease duration, neuropathology, entorhinal cortex, hippocampal formation, amygdala, regional vulnerability, cytoarchitecture
- MeSH terms
- Aged, Alzheimer Disease, Amygdala, Brain, Female, Hippocampus, Humans, Male, Middle Aged, Neurofibrillary Tangles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
